{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:30:48Z","timestamp":1793417448282,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Helsinki","id":[{"id":"https:\/\/ror.org\/040af2s02","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although many studies have estimated the prevalence of chronic kidney disease (CKD) in the general population, few have assessed its cumulative incidence over a long time using both estimated glomerular filtration rate (eGFR) and albuminuria or assessed how CKD occurrence influences mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, population-based cohort study included 1144 Finnish participants aged 40\u201365 years at baseline, who were followed from 1996 to 2019. The study assessed the prevalence of CKD stages 1\u20135 at baseline, 10 years, and 22 years, and examined risk factors for incident CKD, defined as a\u2009\u2265\u200940% decline in eGFR, new-onset proteinuria, or a new kidney disease diagnosis. It also evaluated the association between incident CKD, eGFR decline, and proteinuria and mortality. Multivariable Cox proportional hazards models were used to assess risk factors of incident CKD, and the effect of eGFR decline or proteinuria on mortality.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, the prevalence of CKD was 3.1%. During the follow-up, incident CKD was detected in 14.1% of participants. In multivariable analysis, older age, higher body mass index, diabetes and hypertension were associated with increased risk of CKD. After adjustment for age, incident CKD was associated with 2.31-fold risk of all-cause mortality, and when evaluated separately, proteinuria and a\u2009\u2265\u200940% decline in eGFR were associated with 2.75-fold and 2.37-fold risks, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Incidence of CKD is high in middle-aged Finns and is strongly associated with increased mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-026-04970-6","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T01:44:53Z","timestamp":1776131093000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, risk factors, and mortality impact of chronic kidney disease in middle-aged Finns: a 22-year population-based cohort study"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-6215-0356","authenticated-orcid":false,"given":"Johanna","family":"Sinkko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kati","family":"Kaartinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkka","family":"Kein\u00e4nen-Kiukaanniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaakko","family":"Tuomilehto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannu","family":"Uusitalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jouko","family":"Saramies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrik","family":"Finne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"1","key":"4970_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7\u201311.","journal-title":"Kidney Int Suppl (2011)"},{"issue":"10","key":"4970_CR2","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1093\/ndt\/gfae048","volume":"39","author":"R Duff","year":"2024","unstructured":"Duff R, Awofala O, Arshad MT, Lambourg E, Gallacher P, Dhaun N, et al. Global health inequalities of chronic kidney disease: a meta-analysis. Nephrol Dial Transpl. 2024;39(10):1692\u2013709.","journal-title":"Nephrol Dial Transpl"},{"issue":"4","key":"4970_CR3","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10654-012-9652-3","volume":"27","author":"A Juutilainen","year":"2012","unstructured":"Juutilainen A, Kastarinen H, Antikainen R, Peltonen M, Salomaa V, Tuomilehto J, et al. Trends in estimated kidney function: the FINRISK surveys. Eur J Epidemiol. 2012;27(4):305\u201313.","journal-title":"Eur J Epidemiol"},{"issue":"6","key":"4970_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1093\/ndt\/gfae242","volume":"40","author":"K Metsarinne","year":"2025","unstructured":"Metsarinne K, Bodeg\u00e5rd J, Toppila I, Uusi-Rauva K, Frederiksen LE, Brinkmann S. Characteristics, treatment and disease burden among stage 3\u20134 chronic kidney disease patients with and without type 2 diabetes in Finland during 2016\u20132022. Nephrol Dial Transpl. 2025;40(6):1115\u201323.","journal-title":"Nephrol Dial Transpl"},{"issue":"1","key":"4970_CR5","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pcd.2021.12.012","volume":"16","author":"K Metsarinne","year":"2022","unstructured":"Metsarinne K, Pietila M, Kantola I, Stenman LK, Hatinen OP, Vesikansa A, et al. The majority of type 2 diabetic patients in Finnish primary care are at very high risk of cardiovascular events: A cross-sectional chart review study (STONE HF). Prim Care Diabetes. 2022;16(1):135\u201341.","journal-title":"Prim Care Diabetes"},{"issue":"4","key":"4970_CR6","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/j.xkme.2021.03.014","volume":"3","author":"CD Chu","year":"2021","unstructured":"Chu CD, Chen MH, McCulloch CE, Powe NR, Estrella MM, Shlipak MG, et al. Patient Awareness of CKD: A Systematic Review and Meta-analysis of Patient-Oriented Questions and Study Setting. Kidney Med. 2021;3(4):576\u2013e851.","journal-title":"Kidney Med"},{"issue":"10302","key":"4970_CR7","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0140-6736(21)00519-5","volume":"398","author":"K Kalantar-Zadeh","year":"2021","unstructured":"Kalantar-Zadeh K, Jafar TH, Nitsch D, Neuen BL, Perkovic V. Chronic kidney disease. Lancet. 2021;398(10302):786\u2013802.","journal-title":"Lancet"},{"issue":"6","key":"4970_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.pcd.2021.09.010","volume":"15","author":"J Saramies","year":"2021","unstructured":"Saramies J, Koiranen M, Auvinen J, Uusitalo H, Hussi E, Cederberg H, et al. 22-year trends in dysglycemia and body mass index: A population-based cohort study in Savitaipale, Finland. Prim Care Diabetes. 2021;15(6):977\u201384.","journal-title":"Prim Care Diabetes"},{"issue":"6","key":"4970_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1093\/clinchem\/18.6.499","volume":"18","author":"WT Friedewald","year":"1972","unstructured":"Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499\u2013502.","journal-title":"Clin Chem"},{"issue":"9","key":"4970_CR10","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"19","key":"4970_CR11","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Eng J Med. 2021;385(19):1737\u201349.","journal-title":"N Eng J Med"},{"issue":"4S","key":"4970_CR12","first-page":"S117","volume":"105","author":"Kidney Disease","year":"2024","unstructured":"Kidney Disease. Improving Global Outcomes CKDWG. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117\u2013314.","journal-title":"Kidney Int"},{"issue":"5","key":"4970_CR13","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.kint.2020.06.017","volume":"98","author":"AJ Jonsson","year":"2020","unstructured":"Jonsson AJ, Lund SH, Eriksen BO, Palsson R, Indridason OS. The prevalence of chronic kidney disease in Iceland according to KDIGO criteria and age-adapted estimated glomerular filtration rate thresholds. Kidney Int. 2020;98(5):1286\u201395.","journal-title":"Kidney Int"},{"issue":"2","key":"4970_CR14","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/sj.ki.5002017","volume":"71","author":"K Yamagata","year":"2007","unstructured":"Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007;71(2):159\u201366.","journal-title":"Kidney Int"},{"issue":"10","key":"4970_CR15","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1093\/ndt\/gfw253","volume":"32","author":"GM McMahon","year":"2017","unstructured":"McMahon GM, Hwang SJ, Fox CS. Residual lifetime risk of chronic kidney disease. Nephrol Dial Transpl. 2017;32(10):1705\u20139.","journal-title":"Nephrol Dial Transpl"},{"issue":"12","key":"4970_CR16","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1093\/ndt\/gfw354","volume":"31","author":"A Gasparini","year":"2016","unstructured":"Gasparini A, Evans M, Coresh J, Grams Me, Norin O, Qureshi AR, et al. Prevalence and recognition of chronic kidney disease in Stockholm healthcare. Nephrol Dial Transpl. 2016;31(12):2086\u201394.","journal-title":"Nephrol Dial Transpl"},{"key":"4970_CR17","doi-asserted-by":"publisher","first-page":"sfaf399","DOI":"10.1093\/ckj\/sfaf399","volume":"19","author":"D Kraus","year":"2026","unstructured":"Kraus D, Gieswinkel A, Boedecker-Lips SC, Klimpke P, Storzt M, Schleicher EM, et al. Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health Study. Clin Kidney J. 2026;19:sfaf399.","journal-title":"Clin Kidney J"},{"key":"4970_CR18","doi-asserted-by":"crossref","unstructured":"Shlipak MG, Tummalapalli SL, Boulware LE, Grams ME, Ix JH, Jha V, et al. The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2021;99:34\u201347.","DOI":"10.1016\/j.kint.2020.10.012"},{"issue":"11","key":"4970_CR19","first-page":"660","volume":"147","author":"R Hojs","year":"2023","unstructured":"Hojs R, Ekart R, Bevc S, Vodosek Hojs N. Chronic Kidney Disease Obes Nephron. 2023;147(11):660\u20134.","journal-title":"Chronic Kidney Disease Obes Nephron"},{"issue":"3","key":"4970_CR20","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1093\/ndt\/gfw452","volume":"32","author":"J Xia","year":"2017","unstructured":"Xia J, Wang L, Ma Z, Zhong L, Wang Y, Gao Y, et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transpl. 2017;32(3):475\u201387.","journal-title":"Nephrol Dial Transpl"},{"issue":"6","key":"4970_CR21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1001\/archinte.164.6.659","volume":"164","author":"DS Keith","year":"2004","unstructured":"Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med. 2004;164(6):659\u201363.","journal-title":"Arch Intern Med"},{"issue":"2","key":"4970_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.semnephrol.2022.04.006","volume":"42","author":"MLR Wyld","year":"2022","unstructured":"Wyld MLR, De La Mata NL, Viecelli A, Swaminathan R, O\u00b4Sullivan KM, O\u00b4Lone E, et al. Sex-based Differences in Risk Factors and Complications of Chronic Kidney Disease. Semin Nephrol. 2022;42(2):153\u201369.","journal-title":"Semin Nephrol"},{"issue":"1","key":"4970_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41581-023-00784-z","volume":"20","author":"NC Chesnaye","year":"2024","unstructured":"Chesnaye NC, Carrero JJ, Hecking M, Jager KJ. Differences in the epidemiology, management and outcomes of kidney disease in men and women. Nat Rev Nephrol. 2024;20(1):7\u201320.","journal-title":"Nat Rev Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04970-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04970-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04970-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T03:04:37Z","timestamp":1793415877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04970-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4970"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04970-6","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"4 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Article updated to correct the funding information","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was carried out in accordance with the Declaration of Helsinki, and it was approved by the Ethics Review Board of the South Karelia Hospital District and the research Ethics Committee of the University of Helsinki (HUS\/2203\/2018). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"J. Sinkko: Grants from Finnish Kidney Foundation, Viipuri Tuberculosis Foundation, Antti Matikka Foundation and Finnish Cultural Foundation, and a lecture fee from Duodecim. JT: Support for attending meetings and\/or travel from International Diabetes Federation and East African Diabetes Study Group, stock or stock options from Orion Pharma, Aktivolabs and Digostics, and leadership of the World Community for Prevention of Diabetes (President). HU: Support from Elsemay Bj\u00f6rn Fund. PF: Grants from Finska l\u00e4kares\u00e4llskapet, Liv och H\u00e4lsa and Finnish governmental research funding, consulting fees from Astellas, and a lecture fee from Boehringer-Ingelheim. Other authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"329"}}